Velox BioSystems Aims to Develop 'IC 3D' Microdroplet Technology for Clinical, Other Applications | GenomeWeb

NEW YORK (GenomeWeb) – Harnessing a microfluidic technology initially developed by researchers at the University of California, Irvine, startup Velox Biosystems plans to develop a clinical diagnostic device for rapid identification of rare targets in complex raw samples, such as blood.

The microfluidic technology, called Integrated Comprehensive Droplet Digital Detection, or IC 3D, was developed in the labs of UC Irvine professors Weian Zhao and Enrico Gratton. Velox was co-founded by Zhao and former UC Irvine postdoc Chris Heylman, who now serves as the company's CEO.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.